Novomol achieves positive validation for its in silico discovery engine EDEN

Today, Novomol, a Germany-based life science start-up company focused on computational drug discovery (www.novomol.com), announced early results from a drug discovery collaboration with Ridgeline, a Versant Ventures Discovery Engine located in Switzerland (http://ridgelinediscovery.com).
In this collaboration, Novomol’s in silico platform EDEN was used to identify novel biologically active compounds for one of Ridgelines proprietary molecular targets. 56 compounds with drug-like properties from several different structural classes were synthesized and tested. More then 80% of the compounds were found to be active in the binding assay with the most potent compounds having single digit micromolar activity.
Jochen Böhm, managing director of Novomol, commented: “We are very pleased with the results as they further demonstrate and validate the power of our novel proprietary computational approach. It is clear that drug discovery is still a process with many unknowns and while we may not see such high hit rates across all projects, we see the excellent results from this project as indication that our approach and algorithm can produce validated hits against a range of drug targets.”
Alexander Flohr, SVP Chemistry at Ridgeline, commented: “We are impressed by the results achieved in this collaboration and it has been a pleasure to work with Jochen. The results are a very nice example for demonstrating the impact of Novomol’s differentiated computational approach on drug discovery and early drug-lead finding.”